Cancer Genetics, Inc. Featured in Two Key Latin American Genetics Conferences

RUTHERFORD, N.J., Nov. 21, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, announces its participation in the third annual Latin American Human Genetics Congress and thirty-eighth annual National Human Genetics Congress on November 20 to November 23, 2013 in Riviera Maya, Mexico.

CGI's vice president of research and development, Jane Houldsworth, Ph.D., will conduct a workshop on the Company's proprietary FHACT™ test. Published studies support the use of FHACT™ as an aid in the screening of women with HPV-positive abnormal cervical lesions ( FHACT™ focuses on earlier detection and more accurate genomic-guided decision making of HPV-associated cancers, which can save valuable time in the testing process, while creating substantial cost savings for the healthcare system.

"Our featured position at this week's event is another example of the recognition CGI continues to receive, which further confirms our position as an emerging leader in disease-focused molecular diagnostics," stated Panna Sharma, president and CEO of CGI. "The Latin American market, which we entered in 2010 with our DNA-FISH Probes and expanded in 2012 through our relationship with Roche Servicios, remains a priority for CGI. This week's event provides a tremendous opportunity for us to showcase the benefits of our products to key thought leaders, clinicians and pathologists that will improve patient care in oncology in Latin America.

Cervical cancer is the second most common cancer amongst women in the region (including the Caribbean). Every year, 68,000 women are diagnosed and 32,000 will die of the cancer in the region. By identifying women with biomarkers of cancerous lesions, FHACT™ can aid in reducing the number of biopsies and colposcopies and therefore have a positive impact on cervical cancer screening and management programs.

The third annual Latin American Human Genetics Congress and thirty-eighth annual National Human Genetics Congress take place November 20 to November 23, 2013 in Riviera Maya, Mexico. Organizers anticipate up to 800 attendees, including key members of the Latin American genetics community, representing both industry and academic institutions. Dr. Houldsworth will present "FISH: Past and Future of a Widely-Used Method" at the "Translational Genomics: Present and Future" symposium on November 22, from 9:00 a.m. to 9:30 a.m. Additionally, Dr. Houldsworth will host a workshop, "FHACT™, a New Aid in the Triage of Low-Grade Cervical Lesions," on November 22, from 12:30 p.m. to 1:30 p.m.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended March 31, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 jon@redchip.comSource:Cancer Genetics